US FDA grants Novartis OK to market pediatric Afinitor in rare tumor
This article was originally published in Scrip
Executive Summary
Novartis gained approval in the US of a new pediatric dosage form of its kinase inhibitor everolimus, which will be marketed as Afinitor Disperz as a treatment for subependymal giant cell astrocytoma (SEGA), a rare brain tumor.